HIV prevention and treatment options for teens and young adults in South Africa
Adolescent-tailored HIV treatment and prevention strategies in South Africa: projecting clinical benefits and value
This project uses a computer model to compare long-acting and daily HIV prevention and treatment options for adolescents and young adults in South Africa.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11383407 on NIH RePORTER |
What this research studies
This project uses a computer simulation to project how different HIV prevention and treatment options could affect your health over time if you are a teen in South Africa. The team adapts their CEPAC-AYA model with local data on diagnosis, treatment access, adherence, and the impacts of stigma and disclosure. They will run scenarios comparing long-acting injectables and daily pills to estimate infections prevented, lives saved, and health-care costs. The results are intended to guide which approaches might make HIV care and prevention easier and more effective for you and other young people.
Who could benefit from this research
Good fit: Adolescents and young adults (about ages 10–24) in South Africa who are at risk for HIV or living with HIV.
Not a fit: People outside the adolescent/young adult age range or living in countries with very different HIV epidemics may not directly benefit from the study's specific findings.
Why it matters
Potential benefit: Could identify strategies that lower deaths and new infections and make HIV prevention and treatment easier for adolescents and young adults.
How similar studies have performed: Previous clinical trials and modeling of long-acting HIV drugs have shown promise, but adolescent-focused modeling and real-world data remain limited.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Neilan, Anne — Massachusetts General Hospital
- Study coordinator: Neilan, Anne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.